Isofluran Piramal indications
Inhalation/Respiratory
Induction and maintenance of general anaesthesia
Adult: Induction: Initially, 0.5% v/v with oxygen or oxygen and nitrous oxide, increased to 1.5-3% v/v. Surgical anaesthesia is usually produced within 10 minutes.
Maintenance: 1-2.5% v/v with oxygen and nitrous oxide mixtures or 1.5-3.5% v/v with oxygen only. For maintenance of anesth during caesarean section: 0.5-0.75% v/v with oxygen and nitrous oxide mixtures.
Uses of Isofluran Piramal in details
Isofluran Piramal is used as general anaesthesia for all type of surgeries.
Isofluran Piramal description
lsoflurane is a colourless, nonflammable general inhalation anaesthetic which contains no additive or stabiliser. It is 1-chloro-2,2,2-trifluoroethyl difluoro-melhyl ether.
Isofluran Piramal dosage
lsofurane has a slight pungent ethereal odour, which may limit the rate of gas induction but, despite this, induction and particularly recovery are rapid.
The use Isofluran Piramal-specific vaporisers will facilitate accurate control of the administered concentration of anaesthetic.
The minimum alveolar concentration (MAC) the standard measure of potency for anaesthetics is 1.15% in pure oxygen decreasing to 0.5% when given with 70% nitrous oxide for middle-aged humans. There is an age-relationship, the MAC is significantly higher in children and is lower in the elderly.
Premedication: Premedication drugs should be selected according to the needs of the patient. The ventilatory depressant effect of Isofluran Piramal should be taken into account. Anticholinergic drugs (eg, atropine, glycopyrrolate USP) may be used for their effects in drying oral secretions (antisialogogue) at the discretion of the anaesthetist, but they may enhance the weak effects of Isofluran Piramal in increasing heart rate.
Induction: As Isofluran Piramal has a mild pungency, inhalation should usually be preceded by the use of a short-acting barbiturate or other IV induction agent, to prevent coughing. Salivation and coughing may be troublesome in small children induced with Isofluran Piramal. Alternatively, Isofluran Piramal with oxygen or with an oxygen/nitrous oxide mixture may be administered. It is recommended that induction with Isofluran Piramal be initiated at a concentration of 0.5%. Concentrations of 1.5-3% usually produce surgical anaesthesia in 7-10 min. Blood pressure decreases during induction but this may be compensated by surgical stimulation.
Maintenance: Adequate anaesthesia for surgery may be sustained with an inspired lsoflurane concentration of 1-2.5% in an oxygen/70% nitrous oxide mixture. Additional inspired Isofluran Piramal (0.5-1%) will be required with lower nitrous oxide levels, or when Isofluran Piramal is given with oxygen alone or with air/oxygen mixtures. Blood pressure decreases during maintenance anaesthesia in relation to the depth of anaesthesia. That is, blood pressure is inversely related to the Isofluran Piramal concentration. Provided there are no other complicating factors, this is probably due to peripheral vasodilation. Cardiac rhythm remains stable. Excessive falls in blood pressure may be due to the depth of anaesthesia and in such circumstances can be corrected by reducing the inspired Isofluran Piramal concentration.
Induced hypotension can be achieved by artificially ventilating patients with Isofluran Piramal 2.5-4%. Pretreatment with clonidine significantly decreases the Isofluran Piramal requirement for maintaining induced hypotension.
Recovery: The concentration of Isofluran Piramal can be reduced to 0.5% at the start of closing the operation wound and then to 0% at the end of surgery, provided that the anaesthetist is satisfied that the effect of any neuromuscular blocking drugs has been reversed and the patient is no longer paralysed. After discontinuation of all anaesthetics, the airways of the patient should be ventilated several times with oxygen 100% until complete recovery.
Isofluran Piramal interactions
Muscle Relaxants: Isofluran Piramal produces sufficient muscle relaxation for some intra-abdominal operations. It is compatible with all commonly used muscle relaxants, the effects of which may be markedly potentiated by Isofluran Piramal. The effect is most notable in nondepolarising agents, thus lower doses should be used in the presence of Isofluran Piramal. The effect of nondepolarising muscle relaxants can be counteracted by administering neostigmine as this has no effect on the relaxant properties of Isofluran Piramal.
Adrenaline: Administration of adrenaline (epinephrine) by any route during Isofluran Piramal anaesthesia may cause supraventricular or ventricular arrhythmias. Where adrenaline is used, the amount used should be limited to a maximum of 3 mg/kg of body weight in patients with normal hearts and less in those with rhythm disturbances.
Concurrent use of other β-sympathomimetic drugs eg, amphetamines may predispose to arrhythmias. If possible, interrupt treatment a few days before surgery.
Calcium Antagonists (and Other Vasodilators): Isofluran Piramal can cause marked hypotension in patients receiving concomitant therapy with calcium antagonists, especially those of the dihydropyridine class. Patients receiving chronic therapy with other vasodilators eg, ACE inhibitors (eg, captopril, enalapril, lisinopril) or α1-adrenoceptor antagonists (eg, prazosin), may show unpredictable hypotension with any type of anaesthesia. Monoamine Oxidase Inhibitors (MAOI): Beta-Blockers:
Isoniazid: Isoniazid induces enzymes. Patients receiving isoniazid may be more susceptible to hepatotoxicity from volatile anaesthetics. If possible, cease isoniazid treatment 1 week before surgery. Opioid Analgesics:
Isofluran Piramal side effects
See also:
What are the possible side effects of Isofluran Piramal?
Adverse reactions encountered in the administration of Isofluran Piramal are in general dose dependent extensions of pharmacophysiologic effects and include respiratory depression, hypotension and arrhythmias.
Shivering, nausea, vomiting and ileus have been observed in the postoperative period.
As with all other general anesthetics, transient elevations in white blood count have been observed even in the absence of surgical stress. See WARNINGS for information regarding malignant hyperthermia and elevated carboxyhemoglobin levels.
During marketing, there have been rare reports of mild, moderate and severe (some fatal) postoperative hepatic dysfunction and hepatitis.
Isofluran Piramal has also been associated with perioperative hyperkalemia.
Post-Marketing Events:
The following adverse events have been identified during post-approval use of Isofluran Piramal. Due to the spontaneous nature of these reports, the actual incidence and relationship of Isofluran Piramal, these events cannot be established with certainty.
Cardiac Disorders: Cardiac arrest
Hepatobiliary Disorders: Hepatic necrosis, Hepatic failure
Isofluran Piramal contraindications
Known sensitivity to Isofluran Piramal or to other halogenated agents. Known or suspected susceptibility to malignant hyperthermia. Patients who have developed an icterus and/or fever of unknown origin, hepatic impairment or eosinophilia after administration of Isofluran Piramal or another halogenated anaesthetic.
Active ingredient matches for Isofluran Piramal:
Isoflurane in Slovakia, Tunisia.
List of Isofluran Piramal substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Isofluran Rhodia (Bangladesh, Czech Republic, Slovakia) | |
| Isoflurane (Argentina, Austria, Bangladesh, Bosnia & Herzegowina, Brazil, Bulgaria, Canada, China, Croatia (Hrvatska), Czech Republic, Estonia, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Oman, Peru, Philippines, Poland, Romania, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam) | |
| Liquid; Inhalation; Isoflurane 100% (Raman & Weil) | |
| Liquid; Inhalation; Isoflurane 99.9% (Raman & Weil) | |
| Forane liquid (Raman & Weil) | $ 0.24 |
| ISOFLURANE / RAMAN & WEIL inhalation soln 100 % x 100ml (Raman & Weil) | $ 13.58 |
| ISOFLURANE / RAMAN & WEIL inhalation soln 100 % x 250ml (Raman & Weil) | $ 48.19 |
| Isoflurane liquid 1 mL/mL (Raman & Weil) | |
| Isoflurane - Rhodia Organique Fine (China) | |
| Isoflurane 100% (Cyprus) | |
| Isoflurane 100% Piramal (Malta) | |
| Isoflurane Abbott (Canada) | |
| Isoflurane AbbVie (Canada, Malta, United Kingdom) | |
| Isoflurane acdiam (Egypt) | |
| Isoflurane Adeka (Turkey) | |
| Isoflurane Air Water Inc. (Japan) | |
| Isoflurane Bélamont (France) | |
| Solution; Inhalation; Isoflurane 100% | |
| Isoflurane Belamont (France) | |
| Solution; Inhalation; Isoflurane 100% | |
| Isoflurane Bélamont (France) | |
| Solution; Inhalation; Isoflurane 100% | |
| Isoflurane Dexa Medica (Indonesia) | |
| Isoflurane Dexa Medica 250 mL x 1's (Dexa Medica) | $ 192.20 |
| Isoflurane Fresenius Kabi (Canada) | |
| Isoflurane Halocarbon (Bulgaria, Malaysia) | |
| Isoflurane Halocarbon 100 % x 100 mL | |
| Isoflurane Halocarbon 100 % x 250 mL | |
| Isoflurane MC Pharma 100% (Bulgaria) | |
| Isoflurane Merial (Italy) | |
| Isoflurane Nicholas (United States) | |
| Isoflurane orion (Egypt) | |
| Isoflurane Piramal (Georgia) | |
| Isoflurane Piramal 100 % v/v x 1 Bottle 100 mL (Piramal) | |
| Isoflurane Piramal 100 % v/v x 1 Bottle 250 mL (Piramal) | |
| Isoflurane Piramal inhalation liqd 100% 100 mL x 1's (Piramal) | |
| Isoflurane Piramal inhalation liqd 100% 250 mL x 1's (Piramal) | |
| Isoflurane PSM (New Zealand) | |
| Isoflurane Rhodia (Israel) | |
| Isoflurane t3a (Egypt) | |
| Isoflurane Torrex (Croatia (Hrvatska)) | |
| Isoflurane USP 99.9% Halocarbon Laborat. (Paraguay) | |
| Isoflurane Vet (New Zealand) | |
| Isoflurane Virbac (United Kingdom) | |
| Isoflurane [Usan:Ban:Inn:Jan] | |
| Isoflurane-Medeva Europe (Luxembourg) | |
| Isoflurane-Vet (New Zealand, United Kingdom) | |
| Isoflurane-Vet Merial (New Zealand) | |
| Isoflurano 100% USP Pharmac (Venezuela) | |
See 165 substitutes for Isofluran Piramal | |
References
- DailyMed. "ISOFLURANE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "isoflurane". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "isoflurane". http://www.drugbank.ca/drugs/DB00753 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Isofluran Piramal are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Isofluran Piramal. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
